Alia Bhatt Locked for Extended Appearance in Brahmastra 2 Alongside Ranbir Kapoor and Deepika Padukone

Director Ayan Mukerji is gearing up to bring the next chapter of his fantasy franchise to life, with production on Brahmastra 2 scheduled to commence in April 2027. Amid mounting anticipation surrounding the project, details have emerged regarding the sequel’s evolving cast dynamics. While talks remain ongoing with Deepika Padukone to portray Amrita due to her packed schedule, Alia Bhatt has officially been locked in to reprise her role as Isha in an extended appearance.

Sources reveal that Bhatt will film for approximately 25 days out of the sequel’s planned 125-day principal photography schedule. Although Brahmastra 2 will primarily focus on the origin and conflict between Dev and Amrita, Bhatt’s character remains integral to the overarching narrative arc. Furthermore, Ranbir Kapoor is set to take on a dual role in the sequel, portraying both the central protagonist Shiva and his formidable father, Dev.

Key Narrative and Production Developments

Dual Roles: Ranbir Kapoor will pull double duty, starring as both Shiva and Dev.

Core Focus: The second installment centers heavily on the dynamic between Dev and Amrita, with Deepika Padukone expected to play Dev’s wife.

Expanded Franchise Arc: While Alia Bhatt features in an extended capacity opposite Shiva in Brahmastra 2, she is slated to share screen space with Deepika Padukone as a parallel lead in Brahmastra 3.

Production Timeline: Director Ayan Mukerji has finalized the script, with filming officially targeted to begin in April 2027.

The sequel aims to deepen the complex lore established in the 2022 original while expanding the roles of its primary characters. With Mukerji working continuously to refine the story, the project promises a larger cinematic scale, setting the stage for an interconnected storyline that directly sets up the third installment of the trilogy. Stay tuned to know more about it only with us and if you have anything to share do comment below and share your thoughts.